Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prestige Consumer Healthcare Inc. filings document material events for an operating consumer healthcare company, including 8-K disclosures on quarterly and year-to-date operating results, financial condition and Regulation FD investor presentations. The filings also cover material agreements, capital-structure matters, governance topics and shareholder voting matters tied to the company’s public-company reporting.
These records frame Prestige’s disclosures around its portfolio of over-the-counter healthcare brands, retail distribution markets, and product or regulatory matters when they are material to the business.
Prestige Consumer Healthcare Inc. insider Jeffrey Zerillo, Senior VP Operations, reported a tax-related share disposition. On May 2, 2026, 432 shares of common stock were withheld at $55.09 per share to cover tax obligations. Following this non-market transaction, he directly holds 40,616 shares.
Prestige Consumer Healthcare Inc. Chief Executive Officer Ronald M. Lombardi reported a routine tax-related share disposition. On May 2, 2026, 2,665 shares of common stock were withheld at $55.09 per share to cover tax obligations, a non‑market transaction. Following this event, Lombardi directly holds 343,864 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare EVP Adel Mekhail reported a compensation-related share withholding. On this Form 4, 542 shares of common stock were disposed of at $55.09 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. Following this transaction, Mekhail directly holds 20,366 shares of Prestige Consumer Healthcare common stock.
Prestige Consumer Healthcare Inc. officer William P’Pool reported routine share movements involving company common stock. On May 2, 2026, 599 shares were disposed of at $55.09 per share as a tax-withholding disposition to cover obligations, not as an open-market sale. After this transaction, P’Pool held 22,175 shares directly. A separate indirect entry shows 100 shares held in the P’Pool Family Giving Fund via Fidelity Charitable, reflecting a charitable-related position rather than personal trading.
PBH submitted a Rule 144 notice reporting the proposed sale of 346 shares of Common Stock tied to restricted stock vesting. The filing lists a dollar value of $19,140.72 and references trading on the NYSE. It also discloses a prior sale of 1,000 shares on 02/11/2026 with a reported amount of $65,930.00.
Prestige Consumer Healthcare Inc: Vanguard Capital Management reports beneficial ownership of 2,454,974 shares of common stock, representing 5.18% of the class as of 03/31/2026. The filing shows sole voting power over 361,981 shares and sole dispositive power over 2,454,974 shares. The disclosure states these holdings include securities held for Vanguard funds and managed accounts. The report was signed on 04/30/2026.
Prestige Consumer Healthcare Inc Schedule 13G shows Vanguard Portfolio Management reported beneficial ownership of 2,826,536 shares of Common Stock, representing 5.97% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 2,826,536 shares and sole voting power over 22,708 shares. The form was signed on 04/29/2026.
The Vanguard Group filed Amendment No. 17 to its Schedule 13G/A regarding Prestige Consumer Healthcare Inc. The amendment reports amount beneficially owned: 0 shares representing 0% of Common Stock. It explains an internal realignment effective January 12, 2026 that caused disaggregated reporting by Vanguard subsidiaries. The form is signed by Ashley Grim on 03/27/2026.
Prestige Consumer Healthcare Inc. announced a definitive agreement for its subsidiary Prestige Brands, Inc. to acquire the Breathe Right nasal strip brand and certain other over-the-counter consumer health brands from Foundation Consumer Healthcare for $1.045 billion in cash, or approximately $900 million net of anticipated $150 million tax benefits. The assets include Breathe Right, the leading nasal strip brand in the United States with international sales, and brands such as Dimetapp children’s cough and cold relief. The deal is expected to close in the first half of fiscal 2027, subject to customary closing conditions and antitrust clearance, and will be financed with cash on hand and a new Term Loan facility. Management describes the acquisition as margin-accretive and expects it to increase free cash flow and support faster balance-sheet deleveraging.
Prestige Consumer Healthcare Inc. Senior VP of Operations Jeffrey Zerillo reported an open-market sale of common stock. On February 11, 2026, he sold 1,000 shares of Prestige Consumer common stock at $65.93 per share. After this transaction, he directly owned 41,048 shares of the company’s common stock.